Max Rosett
Finanzdirektor/CFO bei IMMUNOME, INC.
Vermögen: 296 649 $ am 31.05.2024
Aktive Positionen von Max Rosett
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IMMUNOME, INC. | Comptroller/Controller/Auditor | 10.05.2024 | - |
| Geschäftsführer | 02.10.2023 | - | |
| Finanzdirektor/CFO | 02.01.2024 | - | |
| Investor Relations Kontakt | 02.10.2023 | - |
Karriereverlauf von Max Rosett
Ehemalige bekannte Positionen von Max Rosett
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Research Bridge Partners /Venture Capital/
 Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Corporate Officer/Principal | - | 01.11.2023 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Geschäftsführer | 01.03.2022 | 01.10.2023 |
| Corporate Officer/Principal | 01.01.2022 | 01.03.2022 |
Ausbildung von Max Rosett
| Yale University | Undergraduate Degree |
| Georgia Institute of Technology | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Finance |
- Börse
- Insiders
- Max Rosett
- Erfahrung